The Column Group
Venture capitalActively deployingSan Francisco · Pre-Seed–Late Stage · 21 people tracked
Also known as Column Capital Advisors, Llc · THE COLUMN GROUP MANAGEMENT LP
Investment thesis
TCG pursues a science-driven approach to biotech venture capital, emphasizing company formation while retaining the capital resources to support ventures over the long term across both private and public markets. Its ecosystem comprises multiple complementary funds—TCG Platform funds, TCG Opportunity funds, TCG Labs-Soleil, and TCG Crossover (TCGX)—each with a distinct strategy for deploying capital into technology platforms, single assets, and later-stage programs. The funds collaborate to advance biology, chemistry, and technology innovations from inception through exit, aiming to turn scientific discoveries into successful biotech companies.
Source: firm website, verified Aug 25, 2026.
Team · 21 people
from public directories
Founder mafia
2 people who came through The Column Group went on to found or lead other companies.
What they invest in
from 53 of 59 portfolio companiesBiotech ×50Healthtech ×31Deep Tech ×14Medical Devices ×13AI & Machine Learning ×7Digital Health ×5Circular Economy ×1Cleantech ×1
HQs:United States×35New Zealand×1
Who they back
founder profiles across 13 portfolio companiesFounding team size:solo founder×82 founders×13 founders×24+ founders×2
Investments · 59 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 22024 · 62023 · 22022 · 12021 · 32020 · 32017 · 12016 · 12015 · 42014 · 126 dated
Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.
BiotechHealthtechMedical DevicesNew Brunswick, US
Joaquin Duatoin
Co-investorsAisling CapitalAtlas VentureNaviMed CapitalPortland Seed FundSPRINGROCK VENTURESvenBio Partners
ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.
BiotechHealthtechSouth San Francisco, US
Richard Heyman(Chairman, Founder, Scientific Advisory Board)Charles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Jacob M. Chacko(Executive Officer, Director)Dominic Piscitelli(Chief Financial Officer)Pratik Multani(Chief Medical Officer)
Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)Nextech InvestTaiho Ventures, LLC
Tenaya Therapeutics is a clinical-stage biotechnology company developing gene therapies for inherited heart diseases, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
BiotechHealthtechSouth San Francisco, US
Deepak Srivastava, M.D.(Scientific Founder)Eric Olson, Ph.D.(Scientific Founder)Bruce R. Conklin, M.D.(Scientific Founder)Sheng Ding, Ph.D.(Scientific Founder)Saptarsi Haldar, M.D.(Scientific Founder)Eric Hyllengren(Chief Financial Officer)
Co-investorsGV (Google Ventures)venBio Partners
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)Matthew Patterson(Director)Scott Biller(Director)
Board seatJeff Goater· per SEC Form D
Co-investorsAtlas VentureForesite CapitalARCH Venture PartnersDecheng Capital
Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology.
BiotechHealthtechMedical Devices
Bryan E. Stuart(Chief Executive Officer)Marion Dorsch(President and Chief Scientific Officer)
Co-investorsLux CapitalRA CapitalNextech Invest
InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers.
BiotechDeep TechMedical DevicesSeattle, US
K. Chris Garcia(Scientific Founder)Prakash Raman(CEO)Amanda J. Redig(Chief Medical Officer)Scott Lesley(President & CSO)Pamela Holland(SVP of Biology)Sally Johnson(Chief People Officer)
Co-investorsMRL Ventures FundVida Ventures
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.
BiotechHealthtechCambridge, US
Andrew Fraley(Co-founder)Alfica SehgalOMMER CHOHAN(Executive Officer)JAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(CEO)William Ho
Co-investorsAtlas VentureDigitalis VenturesDroia VenturesYK Bioventures
Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Co-investorsSamsara BioCapitalSanofi Ventures
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)Martin Oft(Chief Scientific Officer)Naiyer Rizvi(Chief Medical Officer)Gregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsSamsara BioCapitalBain Capital Life SciencesCanaan PartnersRA CapitalTCG CrossoverDeerfield Management Company+2 more
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechHealthtechAgoura Hills, US
C. Alexander Kamb(Director)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
BoardSrini Akkaraju(Director)in
Board seatDavid Goeddel· per SEC Form D
Co-investorsNextech InvestVida VenturesSamsara BioCapital
Berkeley, US
Board seatPeter SvennilsonTim KutzkeyLarry Lasky· per SEC Form D · $46.9M raise · filed Oct 2020
Co-investorsColumn
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)Matthew Jacobson(Director)David J. Earp(President & CEO)Paul Park(Executive Officer)
BoardThilo Schroeder(Director)in
Board seatJohn JoseyJames EvangelistaPeter Svennilson· per SEC Form D
Co-investorsBerkeley CatalystLifeforce CapitalMission Bay CapitalMission BiocapitalNextech InvestPandect Bioventures+1 more
BiotechHealthtechCambridge, US
Michael R. Cooper(Executive Officer)James E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)Tom Maniatis(Director)
Board seatPeter SvennilsonDavid Goeddel· per SEC Form D · $100M raise · filed Apr 2018
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesVenrockThird Rock Ventures
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardMichael Gladstone(Director)inDerek DiRocco(Director)inJulie Papanek Grant(Director)inDaniel Becker(Director)
Board seatJohn Josey· per SEC Form D · $130M raise · filed Feb 2021
Co-investorsAccess BiotechnologyAtlas VentureCanaan PartnersRA Capital
BiotechWatertown, US
John Ripple(Executive Officer, Director)Jesper Gromada(Executive Officer)H. James Magee(Executive Officer)Roger Perlmutter(Director)
Board seatDavid GoeddelJeenJoo Kang· per SEC Form D · $42M raise · filed Nov 2018
BiotechSouth San Francisco, US
Rekha Hemrajani(Executive Officer)Brian Wong(Executive Officer, Director)
BoardBeth Seidenberg(Director)inWilliam J. Rieflin(Director)Linda Kozick(Director)
Board seatDavid Goeddel· per SEC Form D · $67.1M raise · filed Jun 2019
Co-investorsKleiner Perkins
Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.
BiotechDeep TechHealthtechMenlo Park, US
Colin James Bell Harvey(Director)Brian T. Naughton(Director)Maureen E. Hillenmeyer(Executive Officer, Director)Maureen Hillenmeyer(CEO & Co-Founder)in
BoardAlex Kolich(Director)
Board seatDavid Goeddel· per SEC Form D
Co-investorsB3 HoldingNextech InvestSoftBank Vision Fund8VCCasdin CapitalTwo Sigma Ventures
BiotechBurlingame, US
John Celebi(Executive Officer)Mary Haak-Frendscho(Executive Officer, Director)
BoardJohn Diekman(Director)inCarl Gordon(Director)inRobert Schreiber(Director)
Board seatDavid Goeddel· per SEC Form D · $6.3M raise · filed Jan 2015
Co-investors5AM VenturesOrbiMed
Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies.
BiotechHealthtechNew York City, US
Tom Maniatis(Director)Nancy Thornberry(Executive Officer, Director)Kenneth Clark(Executive Officer)
BoardTerry McGuire(Director)inJoshua Wolfe(Director)in
Board seatTim Kutzkey· per SEC Form D
Co-investorsDns CapitalIllumina VenturesLux CapitalPolaris Partners
Neurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders.
BiotechHealthtechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Executive Officer)Arnold Kriegstein(Director)
BoardRay Kelleher(Director)
Board seatPeter SvennilsonTim KutzkeyDavid Goeddel· per SEC Form D
Co-investorsBerkeley FrontierIaso VenturesYsios CapitalAlexandriaFidelity InvestmentsLYFE Capital+7 more
NGM Bio is a biopharmaceutical company developing NGM120, a GDF15/GFRAL antagonist antibody, to treat conditions rooted in overactivation of the GDF15 pathway.
BiotechHealthtechSouth San Francisco, US
Diana Peng Bockus(Executive Officer, Director)
BoardRoger M. Perlmutter(Director)
Board seatPeter SvennilsonTim Kutzkey· per SEC Form D
Co-investorsRho Ventures
BiotechSouth San Francisco, US
Jin-Long Chen(Executive Officer, Director)William J. Rieflin(Executive Officer, Director)David V. Goeddel(Director)
BoardMark Leschly(Director)David Schnell(Director)
Board seatDavid GoeddelPeter Svennilson· per SEC Form D · $60M raise · filed Feb 2015
Co-investorsForesite CapitalProspect Venture Partners
Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US
Arthur T. Sands(Executive Officer, Director)Gwenn M. Hansen(Chief Scientific Officer)Timothy Kutzkey(Executive Officer, Director)
BoardMark Goldsmith(Director)
Board seatDavid Goeddel· per SEC Form D
Co-investorsBain Capital Life SciencesEcoR1 CapitalForesite CapitalSofinnova Ventures
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Board seatJeff Goater· per SEC Form D · $25M raise · filed Dec 2022
Co-investorsAvego BioScience CapitalOUP (Osage University Partners)Peregrine VenturesAbbVieNovartis Venture Fund
BiotechCambridge, US
Peter Fuhrken(Director)Howard Federoff(Executive Officer, Director)Nick Manusos(Executive Officer, Director)Martin Ostrowski(Executive Officer)Jonathan Yeh(Director)
Board seatJeff Goater· per SEC Form D · $81.8M raise · filed Mar 2024
Co-investorsCure Ventures
HealthtechSan Francisco, US
Alexander Marson(Director)
BoardAadit Shah(Executive Officer)
Board seatTim Kutzkey· per SEC Form D · $15M raise · filed Apr 2024
BiotechSouth San Francisco, US
Anna Berkenblit(Director)Harold Varmus(Director)
BoardCraig Parker(Executive Officer, Director)
Board seatDavid GoeddelTim Kutzkey· per SEC Form D · $50M raise · filed Jun 2020
Co-investors5AM Ventures
A2 Biotherapeutics develops cell therapy technology using the Tmod platform, which applies quantitative drug discovery methods to treat cancer patients.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Jim Robinson(CEO)
Co-investorsSamsara BioCapital
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureDroia VenturesEcoR1 CapitalGV (Google Ventures)JJDCJohnson & Johnson Innovation – JJDC+1 more
Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.
Biotech
Juan Jaen(Founder)in
Co-investorsAisling CapitalDecheng CapitalDroia VenturesEcoR1 CapitalForesite CapitalSLVC+2 more
Co-investorsAlta PartnersARCH Venture PartnersDC Investment PartnersLongwood FundNextech InvestPathway to Cures+6 more
Tau provides formal verification of compiled binaries by generating mathematical proofs of correctness or identifying bugs, addressing risks from AI-assisted code generation and complex software systems.
AI & Machine LearningCybersecurityDeveloper ToolsEnterprise SoftwareSan Francisco, US
Pedro Nobre(Founder)inLuke Johnston(Founder)in
Co-investorsY CombinatorLux Capital
Cajal Therapeutics develops novel therapies through translating scientific advances into treatments for patients.
AI & Machine LearningBiotechMedical DevicesSeattle, US
Andrew Dervan(Co-Founder and Co-Chief Executive Officer)inIan Peikon(Co-Founder and Co-Chief Executive Officer)inRob Hershberg(Co-Founder and Executive Chairman)
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestProspect Venture PartnersRho Capital PartnersRho Ventures+2 more
Kenai Therapeutics develops iPSC-derived cell therapies and gene-modified medicines for neurodegenerative diseases, particularly Parkinson's disease, leveraging induced pluripotent stem cell technology to replace damaged neurons and restore neural function.
BiotechDeep TechHealthtechMedical Devices
Howard Federoff(Scientific Co-Founder, Chief Medical Officer and Executive Vice President of Corporate Medicine and Science)
Co-investorsCure Ventures
Kimia develops a drug discovery platform called ATLAS that combines active learning, automated chemical synthesis, high-throughput screening, and machine learning to design and optimize novel drug molecules.
AI & Machine LearningBiotechDeep Tech
Stig Hansen(Founder)in
Co-investorsHorizons VenturesAirTree VenturesBlackbird VenturesDIMENSIONDimension CapitalSkip Capital
Lyterian Therapeutics develops pharmaceutical treatments by leveraging protein homeostatic mechanisms to target genetically-validated disease drivers.
BiotechDeep TechHealthtechSouth San Francisco, US
NILO develops technology to upcycle hard-to-recycle plastic waste, primarily polyethylene (PE) and polypropylene (PP), into materials for use in circular systems and safer products.
Circular EconomyCleantechNew Materials
Co-investorsArc AngelsIcehouse VenturesDCVC BioLux Capital
BiotechNew York, US
Jeff Goater(Executive Officer, Director)
BoardTim Kutzkey(Executive Officer, Director, Promoter)
Co-investorsDCVC (Data Collective)DCVC BioLux Capital
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtech
Co-investorsDCVC BioLux Capital
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
Co-investorsNextech InvestVida Ventures
Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
AI & Machine LearningBiotechDeep TechSan Diego, US
Michael Martin, Ph.D.(Chief Executive Officer, President)Jorge F. DiMartinoMichael Martin(President, Chief Executive Officer)Stephen Mullennix(Executive Officer)
BoardSerge Messerlian(Director)inCariad Chester(Director)in
Co-investorsCRV (Charles River Ventures)DCVC (Data Collective)M VenturesNeotribe VenturesSoftBank Vision FundTCG Crossover+1 more
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases.
BiotechHealthtech
Co-investorsFrazier Life SciencesKleiner PerkinsSolasta VenturesOrbiMed
Santa Monica, US
Michael Einziger(Executive Officer, Director)Edna Coryell(Executive Officer, Director)Katherine Power(Director)Jessica Goldin(Executive Officer, Director)
BoardAnn Marie Simpson(Director)
Co-investors8VCDroia VenturesFrazier Life SciencesNovartis Venture FundRTW Investments L.P.Thuja Capital+1 more
Carmot Therapeutics is a clinical-stage biopharmaceutical company developing drug candidates for obesity and type 2 diabetes, including injectable GLP-1/GIP receptor agonists (CT-388, CT-868) and an oral small molecule GLP-1 receptor agonist (CT-996).
BiotechDeep TechDigital Health
Co-investorsHorizons VenturesTCG Crossover
BiotechHealthtech
Co-investorsClal Biotechnology IndustriesExSight VenturesLongitude CapitalTachyon Ventures
Co-investorsEcoR1 CapitalHorizons VenturesLux CapitalTCG CrossoverInnovation Endeavors
BiotechSan Diego, US
Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)
BoardAndrew Schwab(Director)in
Co-investors5AM VenturesAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesAbingworth+3 more
Co-investorsArtis VenturesRidgeback Capital
Nexoplex Bio develops immunotherapies designed to target tumors through recognition of HLA-peptide complexes using multi-specific antibodies, aimed at cancers including certain lung, gastric, esophageal, head and neck, and cervical cancers.
BiotechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
Co-investorsFrazier Life SciencesGV (Google Ventures)
Merck is a pharmaceutical company focused on developing medicines and vaccines for patients globally, guided by a science-led innovation strategy.
BiotechHealthtechMedical DevicesRahway, US
Co-investorsAisling CapitalAtlas VentureHM Venture PartnersSanderling VenturesSPRINGROCK VENTURES
Monimoit develops cancer therapeutics by combining chemical proteomics, covalent-based molecular technologies, and patient-derived translational insights to target difficult-to-drug cancer-promoting proteins and overcome resistance to existing treatments.
BiotechDeep Tech
Revolution Medicines is a clinical-stage oncology company developing targeted cancer therapies based on its tri-complex platform and RAS(ON) inhibitor biology.
BiotechHealthtech
Co-investorsGen CapitalIllinois VenturesNextech Invest
Co-investorsAisling CapitalKleiner PerkinsNew Enterprise Associates (NEA)
Surrozen develops multifunctional antibody therapeutics that modulate the Wnt signaling pathway and other disease drivers, using a proprietary antibody-engineering platform.
BiotechHealthtech
Co-investorsAccess Biotechnology
SyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists.
AI & Machine LearningBiotechDeep Tech
Maria Soloveychik(PhD)
Co-investorsNorth South VenturesOMX Ventures8VC
Tortugas Neuro is a neuroscience drug development company focused on the neurology and neuropsychiatry space, working to advance clinical-stage therapies for brain health.
BiotechHealthtech
Co-investorsAN Venture PartnersCure Ventures
Topo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases.
BiotechHealthtechCambridge, US
Hui Tian(Executive Officer, Director)Madgalene Moran(Executive Officer, Director)Magdalene Moran(Chief Executive Officer)
BoardKarin Kleinhans(Director)Bruce Bean(Director)James Jeffrey Goater, Jr.(Director)
Co-investorsSR One Capital ManagementMRL Ventures Fund
Tr1X is a biopharmaceutical company developing cell and gene therapies to cure autoimmune and inflammatory diseases with high unmet medical need.
BiotechDeep TechHealthtechMedical Devices
David(Co-Founder)Maria Grazia Roncarolo(Co-Founder, President and Head of R&D)
Co-investorsNeva Sgr.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 4
IPOs and acquisitions across the tracked portfolioJohnson & JohnsonNYSE: JNJORIC PharmaceuticalsNASDAQ: ORICTenaya TherapeuticsNASDAQ: TNYAConstellation Pharmaacq. by Novartis
Portfolio news
latest coverage across their companies
Arcus Biosciences · pluang.com · Aug 19, 2026
Tenaya Therapeutics · investing.com · Aug 18, 2026
Ribon Therapeutics · geekwire.com · Aug 14, 2026
Surrozen · simplywall.st · Aug 8, 2026
ORIC Pharmaceuticals · manilatimes.net · Aug 7, 2026
Nura Bio · biospace.com · Jul 30, 2026
Atavistik Bio · biospace.com · Jul 30, 2026
Fund performance · per public LP disclosures · 6
as of Nov 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| The Column Group Fund Opportunity Fund IIILPs: Employees' Retirement System of Rhode Island, Carnegie Corporation of New York | 2022 | — | 0.2% | 1.01x | 0.34x |
| The Column Group Fund VLPs: Employees' Retirement System of Rhode Island, Carnegie Corporation of New York | 2022 | — | -19.1% | 0.77x | 0.00x |
| Column Group IVLPs: The Regents of the University of California | 2019 | — | -1.8% | 0.95x | 0.07x |
| Column Group IIILPs: The Regents of the University of California | 2016 | — | 7.7% | 1.25x | 0.78x |
| Column Group IILPs: The Regents of the University of California | 2014 | — | 7.8% | 2.40x | 1.88x |
| The Column Group, L.P.LPs: The Regents of the University of California | 2005 | — | 23.4% | 2.10x | 0.79x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has The Column Group made?
- The Column Group has 42 tracked investments, including 4 dated in the last 24 months.
- What stage does The Column Group invest at?
- The Column Group invests at the Pre-Seed, Seed, Series A, Series B, Growth, Late Stage stages.
- What is The Column Group's typical check size?
- The Column Group typically writes checks of $30M.
- What sectors does The Column Group focus on?
- The Column Group focuses on Biotech, Deep Tech.
- Where is The Column Group located?
- The Column Group is headquartered in San Francisco, US.
- Does The Column Group lead rounds?
- The Column Group typically participates in rounds rather than leading them.
- Who does The Column Group co-invest with?
- The Column Group most often shares deals with Nextech Invest, Atlas Venture, EcoR1 Capital, among 71 tracked co-investors.
Images
Co-investors · 38
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
Lux Capital is a venture capital firm that backs founders building transformative deep technologies, having been among the first investors in category-defining companies across AI, robotics, biotech, defense, and infrastructure.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
▶26 more co-investors
Vida VenturesCure VenturesDCVC (Data Collective)Canaan PartnersTwo Sigma VenturesARCH Venture PartnersOrbiMedOUP (Osage University Partners)Sanofi VenturesInnovation EndeavorsDimension CapitalSR One Capital ManagementThird Rock VenturesPivotal Life SciencesLeaps by BayerGeneral CatalystFounders FundUS Venture PartnersGeneral AtlanticM12 (Microsoft's Venture Fund)Versant VenturesMPM BioImpactPfizer Venture InvestmentsOmega FundsLightstone VenturesAstellas Venture Management LLC
Firms observed investing alongside The Column Group, from public investor directories. Shared companies are the overlap with The Column Group's recorded portfolio.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Inveready is a Spanish alternative investment firm founded in 2008, offering investment solutions and wealth management services across the small and mid-market segment in Spain.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Octopus Ventures is a founder-focused European venture capital firm that backs mission-driven startups across seven core sectors, investing from idea stage through growth with a focus on pre-seed to Series A.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.